Even though there is broad consensus in the health-related neighborhood that principal PCI is the ideal remedy for heart assault patients when it can be delivered promptly, there is no agreement about the greatest accompanying drug routine, which normally entails a blend of antiplatelet and antithrombotic medication. The part of one particular antithrombotic, bivalirudin (Angiomax, The Medicines Firm) has been notably uncertain since it is far much more costly than its alternative, unfractionated heparin.
HEAT-PPCI was made to aid settle this dilemma. The investigators ran a large, sensible clinical trial that instantly randomized all main PCI sufferers at the Liverpool Heart and Chest Hospital in the Uk. The outcomes of the trial, which have been the topic of considerable debate when they had been presented at the American College of Cardiology meeting earlier this yr, have now been published in the Lancet, along with two editorials that tackle the controversies engendered by the trial.
one,829 sufferers have been randomized in the HEAT-PPCI trial to either heparin or bivalirudin. The final results did not show any advantage for bivalirudin. There was a considerable increase in the principal efficacy outcome– a composite of death, stroke, reinfarction, or unplanned target lesion revascularization– in the bivalirudin group compared with the heparin group (8.seven% versus 5.7%, RR one.53, CI 1.09-two.13, p=.01). There was no significant distinction in the incidence of major bleeding (3.5% versus three.one%, p-.59). The use of bailout GP IIb/IIIa inhibitors was comparable in both groups: 13% for bivalirudin and 15% for heparin.
The authors conclude that their trial “suggests that the use of heparin, rather than bivalirudin confers substantial benefit in the avoidance of major adverse occasions. This locating may well give an possibility, uncommon in modern day overall health care, to give improved outcomes at much diminished price. In our centre, routine use of heparin (rather than bivalirudin, which fees about 400 occasions as a lot) would reduce quick drug costs in our yearly 1000 PPCI instances by £500 000.”
In an accompanying editorial, Peter Berger and James Blankenship say that the distinction in findings among HEAT-PPCI and earlier trials can be explained by many factors, such as the lower use of GP IIb/IIIa inhibitor in conjunction with heparin in HEAT-PPCI, the use of greater doses of heparin in earlier studies, and the better use of radial access in HEAT-PPCI. The trial, they compose, “provides strong proof that bivalirudin alone compared with 70 U/kg of heparin alone (with infrequent bailout use of GP IIb/IIIA inhibitors in each arms), with radial entry for STEMI percutaneous coronary intervention, seems to be inferior to heparin as administered in this trial. Even if heparin alone had produced statistically similar outcomes to bivalirudin, it would have been a win for heparin. A drug that charges significantly less than a 400th of an additional that has comparable efficacy and safety ought be utilised preferentially.”
In a second editorial David Shaw dismisses the intense criticism from some prominent critics of the trial’s ethics based on the truth that trial participants did not offer informed consent till following they had been randomized. Rather, he writes, “HEAT-PPCI is not only an extraordinary achievement in medical analysis, but also in ethical study style. Far from becoming unethical, the research sets a large standard for consent in pragmatic trials.”
Delayed consent “was preferable to attempting to acquire consent from potentially incompetent individuals needing really urgent cardiac treatment… The use of delayed consent is specifically appropriate in pragmatic comparative effectiveness trials the place the two medicines below investigation are each used for licensed indications in problems of equipoise. In regimen clinical care, it would be completely standard for a physician to select either heparin or bilvalirudin with no involvement of the patient in the determination.”
The results of the trial also “mean that assets will not be wasted on bivalirudin, a much more pricey and much less successful treatment than heparin.” Shaw observes: “Unsurprisingly, significantly of the opposition to HEAT-PPCI has come from medical professionals with shut industry ties.”
Controversial Trial Finds No Benefit For Pricey Medicines Firm Drug
Hiç yorum yok:
Yorum Gönder